Polycystic Ovary Syndrome
Serum chemerin may serve as a biomarker to identify pregnant women with polycystic ovary syndrome who are at particular risk for later abortion, and who may benefit from prevention strategies.
Metformin treatment during pregnancy did not influence the metabolic profile in women with polycystic ovary syndrome at 7.7 years of follow-up.
These data confirmed the increased risk for psychiatric disorders in women with PCOS, and indicated an increased risk for ADHD and ASD in their children.
Researchers evaluated the association between PCOS and psychiatric outcomes, as well as whether rates of autism spectrum disorder and attention-deficit/hyperactivity disorder are higher in children of mothers with PCOS.
Metformin treatment during pregnancy may improve outcomes in women with polycystic ovary syndrome.
Children exposed to metformin had higher BMI and increased prevalence of overweight/obesity at 4 years of age.
Variable improvements in menses, hormones, and metabolism were seen during 24 months of metformin use in 119 women with PCOS sub-grouped by baseline weight and androgen status.
Study evaluated the difference in the rate of ongoing pregnancy or live birth between frozen embryo transfer and fresh embryo transfer in women without polycystic ovary syndrome who were undergoing IVF.
While hirsutism may indicate metabolic abnormalities, acne and androgenic alopecia are associated with other clinical hyperandrogenism manifestations.
Among women with polycystic ovary syndrome, type two diabetes was more common and diagnosed at a younger age than in control groups.
Two studies examined the efficacy of acupuncture therapy for stress incontinence and PCOS, finding mixed results.
Data from a systematic review and meta-analysis confirmed a higher risk of anxiety and depression in PCOS, but underlying factors are still unclear.
The highest prevalence of metabolic syndrome in women with polycystic ovary syndrome in the United States occurred in black women.
Researchers examined the efficacy of combination SPIOMET therapy vs oral contraceptive for reducing ectopic fat and restoring normalized ovulation in adolescents with PCOS.
In a follow-up to the PregMet study, researchers examined the long-term metabolic effects of metformin therapy in pregnancy with polycystic ovarian syndrome.
An international survey shows that women with polycystic ovary syndrome are dissatisfied with the information they receive and the length of time to diagnosis.
Resveratrol decreased levels of adrenal and ovarian androgens in women with polycystic ovary syndrome.
Women experienced weight loss as well as decreases in ovarian volume and markers of androgen excess.
For women with polycystic ovary syndrome (PCOS) seeking infertility treatment, the use of frozen embryos rather than fresh appears to improve the chances for a successful pregnancy.
Soy isoflavones were associated with lower levels of circulating insulin and biological markers of insulin resistance in polycystic ovary syndrome.
The diagnosis and management of polycystic ovary syndrome (PCOS) was discussed in a case vignette published in The New England Journal of Medicine.
A portion of women with polycystic ovary syndrome may experience excess adrenal hormone production.
Four randomized controlled trials show benefits for metformin and oral contraceptive pills.
Risk for asthma was increased by 34% in women with polycystic ovary syndrome.
Researchers concluded that including androstenedione in the diagnosis of biochemical hyperandrogenism led to a prevalence of hyperandrogenic PCOS of more than 80%.
Analyses of 3 databases show use for metabolic syndrome, PCOS, and obesity.
Preconception interventions designed to induce weight loss in women with PCOS improved metabolic parameters and ovulation rates.
Children born to mothers with polycystic ovary syndrome may be more likely to have autism spectrum disordes
Hyperandrogenic anovulation for more than 2 years distinguishes PCOS from physiologic anovulation, according to the review.
Researchers noted that fracture risk reduction was more pronounced in women diagnosed before age 30 years.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- New Romosozumab BLA Includes Data from Additional Osteoporosis Trials
- Impact of Maternal Diabetes on Outcomes in Very Preterm, Very Low-Birth-Weight Infants
- Age-Related Differences in Manifestation of Cushing Disease Identified